Horizon purchased those rights for $45 million while Nuvo retains the rights to Pennsaid outside of the U.S. Interestingly, the press release for that 2014 sale noted that there are six U.S. patents protecting Pennsaid, not just the four patents asserted in the Actavis and Lupin cases. Horizon's most recent quarterly earnings report noted that the company had a binding purchase agreement in early June with Nuvo, which manufactures and supplies Pennsaid to Horizon, for $4.4 million worth of Pennsaid through September of this year. Net sales of Pennsaid for the three months ending June 30th were $72.7 million, a 147 percent increase in the $29.4 million in net sales seen during the three months ending June 30th, 2016, making Pennsaid the top seller for Horizon during the recent quarter. $26.7 million worth of net sales growth was attributed to higher net pricing and another $16.5 million was gained through higher prescription volumes.